Inhibitor Therapeutics Inc
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal… Read more
Market Cap & Net Worth: Inhibitor Therapeutics Inc (INTI)
Inhibitor Therapeutics Inc (OTCQB:INTI) has a market capitalization of $8.80 Million ($8.80 Million) as of March 18, 2026. Listed on the OTCQB stock exchange, this USA-based company holds position #32139 globally and #10551 in its home market, demonstrating a -27.14% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Inhibitor Therapeutics Inc's stock price $0.05 by its total outstanding shares 172573545 (172.57 Million).
Inhibitor Therapeutics Inc Market Cap History: 2015 to 2025
Inhibitor Therapeutics Inc's market capitalization history from 2015 to 2025. Data shows change from $22.43 Million to $8.80 Million (-10.12% CAGR).
Inhibitor Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Inhibitor Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of INTI by Market Capitalization
Companies near Inhibitor Therapeutics Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Inhibitor Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Inhibitor Therapeutics Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Inhibitor Therapeutics Inc's market cap moved from $22.43 Million to $ 8.80 Million, with a yearly change of -10.12%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $8.80 Million | -33.77% |
| 2024 | $13.29 Million | -16.30% |
| 2023 | $15.88 Million | -7.07% |
| 2022 | $17.08 Million | -34.00% |
| 2021 | $25.89 Million | +328.57% |
| 2020 | $6.04 Million | -37.28% |
| 2019 | $9.63 Million | -7.00% |
| 2018 | $10.35 Million | -76.10% |
| 2017 | $43.32 Million | -35.64% |
| 2016 | $67.30 Million | +200.00% |
| 2015 | $22.43 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Inhibitor Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.80 Million USD |
| MoneyControl | $8.80 Million USD |
| MarketWatch | $8.80 Million USD |
| marketcap.company | $8.80 Million USD |
| Reuters | $8.80 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.